ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing
ImmunityBio shares rose about 6.5% in premarket trading after the company said the FDA requested more data to support expanding ANKTIVA’s approved uses. ImmunityBio plans to submit the information within 30 days and does not expect to launch a new trial. Director Barry J. Simon disclosed recent stock sales. Traders are watching for the FDA’s response.